Ardelyx Inc. (ARDX) experienced a significant pre-market surge of 5.39% on Tuesday, marking a notable upward movement for the pharmaceutical company's stock.
The price increase appears to be linked to a regulatory filing showing that David M. Mott, a director of Ardelyx, acquired common shares of the company. Insider purchases are often viewed by investors as a positive signal, indicating confidence in the company's future prospects and potential undervaluation of the stock.